Emerging Markets Earnings Roundup: Bayer, Novo Nordisk, Teva (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Newer drugs at Bayer helped the bottom line in the third quarter while the world’s top insulin maker Novo Nordisk missed expectations, but held out emerging markets as a bright spot. Teva tussled with analysts on the surprise exit of Jeremy Levin and said that many of the plans during his brief tenure were driven by the board and remain in place.
You may also be interested in...
Pricing Becomes Crucial Factor For Novo Nordisk’s Growth
The Danish diabetes drug maker is a commanding player in the market, but pushback from reimbursement authorities around the world is placing the company’s future growth prospects under scrutiny.
Stronger Euro Could Make Bayer’s Full-Year Sales Target “Ambitious”
The German conglomerate highlights sales of its five new medicines that have gotten off to good starts in the marketplace and has identified another five early stage cardiology and oncology products to push through its pipeline.
Levin Resigns Unexpectedly, Street Grills Teva’s Chairman On Viability Of Corporate Governance
Chairman Philip Frost cited “slight differences” with Teva’s board as the reason that Jeremy Levin resigned. Analysts on a same day call grilled the chairman on Teva’s practice to deny corporate executives a seat on its board, and on the resulting misalignment of board and management objectives.